Prasugrel

What is Prasugrel?

Prasugrel is an oral antiplatelet medication that belongs to the class of drugs known as P2Y12 receptor antagonists. It is primarily used to prevent blood clots in patients with acute coronary syndrome who are undergoing percutaneous coronary intervention (PCI), such as angioplasty or stent placement. This medication works by reducing the ability of platelets to stick together and form dangerous clots in blood vessels.

Uses

Prasugrel is approved and commonly used for several cardiovascular conditions:

• Acute coronary syndrome with PCI: Primary indication for patients undergoing angioplasty or stent placement to prevent clot formation around the stent
• Prevention of stent thrombosis: Reduces risk of blood clots forming in coronary artery stents, which could cause heart attack
• Secondary prevention after heart attack: Used in combination with aspirin to prevent future cardiovascular events in high-risk patients
• Unstable angina management: Helps prevent progression to heart attack in patients with unstable chest pain scheduled for invasive procedures
• Non-ST elevation myocardial infarction: Reduces risk of recurrent cardiovascular events when used as part of dual antiplatelet therapy

How it works

Prasugrel is a prodrug that becomes active after being metabolized in the liver. Once activated, it irreversibly blocks P2Y12 receptors on platelets, which are essential for platelet activation and aggregation. By preventing platelets from clumping together, prasugrel significantly reduces the formation of blood clots that could block coronary arteries and cause heart attacks.

Side effects

Common side effects:

Submit Your Paper

• Easy bruising
• Minor bleeding (nosebleeds, bleeding gums)
• Headache
• Dizziness
• Back pain
• Fatigue
• Nausea
• Cough

Serious side effects requiring immediate medical attention:

• Major bleeding (gastrointestinal, intracranial, or other severe bleeding)
• Signs of stroke (sudden weakness, confusion, vision changes)
• Unusual bleeding that won’t stop
• Severe allergic reactions (rash, swelling, difficulty breathing)
• Thrombotic thrombocytopenic purpura (rare blood disorder)

Warnings and precautions

• Bleeding risk: Patients with active bleeding, history of stroke, or increased bleeding risk should generally avoid prasugrel due to significantly elevated bleeding potential
• Age restrictions: Generally not recommended for patients 75 years or older due to increased bleeding risk, except in high-risk situations where benefits may outweigh risks
• Weight considerations: Patients weighing less than 60 kg have higher bleeding risk and may require dose adjustment or alternative therapy
• Surgical procedures: Should be discontinued 7 days before elective surgery due to bleeding risk, though timing depends on procedure urgency
• Pregnancy and breastfeeding: Limited safety data available; use only when potential benefits justify risks to mother and fetus

Interactions

• Warfarin and anticoagulants: Significantly increases bleeding risk when combined with blood thinners
• Aspirin: Often prescribed together but increases bleeding risk; requires careful monitoring
• NSAIDs (ibuprofen, naproxen): Can increase bleeding risk and reduce kidney function when combined
• Omeprazole: May reduce prasugrel effectiveness by affecting its metabolism
• Rifampin: May decrease prasugrel effectiveness by increasing its metabolism
• Ketoconazole: Can increase prasugrel levels and bleeding risk
• Ginkgo biloba: May increase bleeding risk when combined with prasugrel
• St. John’s wort: May reduce prasugrel effectiveness by affecting drug metabolism

Check interactions with the GMJ Interaction Checker

Dosage

The typical adult dosage for prasugrel begins with a loading dose of 60 mg taken once, followed by a maintenance dose of 10 mg once daily. For patients weighing less than 60 kg, the maintenance dose is typically reduced to 5 mg once daily. Prasugrel is usually prescribed in combination with aspirin as dual antiplatelet therapy, with treatment duration typically ranging from 12 months to several years depending on individual risk factors. All dosing decisions should be made by a healthcare provider based on individual patient factors, bleeding risk assessment, and specific cardiovascular conditions.

Sources: FDA DailyMed drug labels (public domain), BNF, WHO Essential Medicines List. This article is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before starting or stopping any medication.

This work is licensed under Creative Commons Attribution 4.0 International (CC BY 4.0). You are free to share and adapt this content with attribution to GMJ News (news.gmj.ge).